Showing 5541-5550 of 9431 results for "".
Multi-Faceted approaches to rosacea Management
https://practicaldermatology.com/topics/general-topics/multi-faceted-approaches-to-rosacea-management/22919/Patients are increasingly using cosmeceuticals—with and without prescription agents— to manage symptoms of rosacea.Neurotoxin Tips for Beginners and Advanced Users
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/neurotoxin-tips-for-beginners-and-advanced-users/21578/Experts from the international aesthetics arena share pearls for maximizing neurotoxins.Update on the Treatment of Actinic Keratoses
https://practicaldermatology.com/topics/general-topics/update-on-the-treatment-of-actinic-keratoses/21630/From mainstay therapies to newly approved agents, treatment options for actinic keratoses are growing.Rosacea: Choosing Among the Topical and Systemic Therapeutic Options
https://practicaldermatology.com/topics/general-topics/rosacea-choosing-among-the-topical-and-systemic-therapeutic-options/21706/As the field of therapies available for rosacea has expanded, clinicians must weigh the topical and oral treatment options on a case-by-case basisUpadacitinib and Cardiovascular Events in AD
https://practicaldermatology.com/issues/october-2025/upadacitinib-and-cardiovascular-events-in-ad/39755/A recent review examined whether upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor approved for atopic dermatitis (AD) and other chronic inflammatory diseases, may—despite a boxed warning to the contrary—confer cardioprotective and thromboprotective effects.Advances in the Treatment of Reticular Erythematous Mucinosis
https://practicaldermatology.com/youngmd-connect/resident-resource-center/advances-in-the-treatment-of-reticular-erythematous-mucinosis/23491/Considering nicotinamide’s anti-inflammatory properties for inflammatory dermatological conditions to avoid steroid and antibiotic overuse.Choosing a Systemic Treatment for Elderly Patients with Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/choosing-a-systemic-treatment-for-elderly-patients-with-atopic-dermatitis/60990/These findings challenge long-held fears about using systemic agents in the elderly population.The Microbiome in Acne: Where are We Now?
https://practicaldermatology.com/topics/acne-rosacea/the-microbiome-in-acne-where-are-we-now/23731/As research reveals connections of the microbiome to skin disease, clinicians may discover new approaches to managing the disease.Study Highlights Top-Rated Dermatology Education Apps
https://practicaldermatology.com/topics/practice-management/study-highlights-top-rated-dermatology-education-apps/23565/Researchers rated apps based on four key features.GLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a mu